Prediction of Distant Metastases in Patients with Kidney Cancer Based on Gene Expression and Methylation Analysis
-
Published:2023-07-06
Issue:13
Volume:13
Page:2289
-
ISSN:2075-4418
-
Container-title:Diagnostics
-
language:en
-
Short-container-title:Diagnostics
Author:
Apanovich Natalya1ORCID, Matveev Alexey2, Ivanova Natalia3, Burdennyy Alexey3ORCID, Apanovich Pavel1, Pronina Irina3ORCID, Filippova Elena3, Kazubskaya Tatiana2, Loginov Vitaly3, Braga Eleonora13ORCID, Alimov Andrei1ORCID
Affiliation:
1. Research Centre for Medical Genetics, 1 Moskvorechye St., Moscow 115522, Russia 2. Federal State Budgetary Institution (N.N. Blokhin National Medical Research Center of Oncology) of the Ministry of Health of the Russian Federation, 24 Kashirskoe Shosse, Moscow 115478, Russia 3. Institute of General Pathology and Pathophysiology, Baltijskaya St. 8, Moscow 125315, Russia
Abstract
Clear cell renal cell carcinoma (ccRCC) is the most common and aggressive histological type of cancer in this location. Distant metastases are present in approximately 30% of patients at the time of first examination. Therefore, the ability to predict the occurrence of metastases in patients at early stages of the disease is an urgent task aimed at personalized treatment. Samples of tumor and paired histologically normal kidney tissue from patients with metastatic and non-metastatic ccRCC were studied. Gene expression was analyzed using real-time PCR. The level of gene methylation was evaluated using bisulfite conversion followed by quantitative methylation-specific PCR. Two groups of genes were analyzed in this study. The first group includes genes whose expression is significantly reduced during metastasis: CA9, NDUFA4L2, EGLN3, and BHLHE41 (p < 0.001, ROC analysis). The second group includes microRNA genes: MIR125B-1, MIR137, MIR375, MIR193A, and MIR34B/C, whose increased methylation levels are associated with the development of distant metastases (p = 0.002 to <0.001, ROC analysis). Based on the data obtained, a combined panel of genes was formed to identify patients whose tumors have a high metastatic potential. The panel can estimate the probability of metastasis with an accuracy of up to 92%.
Funder
Ministry of Science and Higher Education of the Russian Federation for Research Centre for Medical Genetics and for the Institute of General Pathology and Pathophysiology
Subject
Clinical Biochemistry
Reference84 articles.
1. Makino, T., Kadomoto, S., Izumi, K., and Mizokami, A. (2022). Epidemiology and Prevention of Renal Cell Carcinoma. Cancers, 14. 2. Ljungberg, B., Albiges, L., Bedke, J., Bex, A., Capitanio, U., Giles, R.H., Hora, M., Klatte, T., Marconi, L., and Powles, T. (2023, March 01). EAU Guidelines on Renal Cell Carcinoma; EAU Annual Congress Milan; 2023; ISBN 978-94-92671-19-6. Available online: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Renal-Cell-Carcinoma-2023.pdf. 3. Kaprin, A., Starinsky, V., and Shakhzadova, A. (2021, March 01). Malignant Neoplasms in Russia in 2020 (Morbidity and Mortality); Moscow; Russia; 2021; ISBN 978-5-85502-268-1. Available online: https://oncology-association.ru/wp-content/uploads/2021/11/zis-2020-elektronnaya-versiya.pdf. 4. The State of Oncology Care in Russia. Kidney Cancer (Morbidity, Mortality, Index of Accuracy, One-Year and Year-by-Year Mortality, Histological Structure). Part 1;Merabishvili;Onkourologiya,2021 5. Classification of Renal Cell Tumors—Current concepts and use of ancillary tests: Recommendations of the Brazilian Society of Pathology;Athanazio;Surg. Exp. Pathol.,2021
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|